Work

Supplementary Figure 5 from Enhancement of Synthetic Lethality via Combinations of ABT-888, a PARP Inhibitor, and Carboplatin In Vitro and In Vivo Using BRCA1 and BRCA2 Isogenic Models

Year: 2023

Type: supplementary-materials

Abstract: PDF file, 240K, SUPPLEMENTARY FIGURE S5. RAD51 foci formed in cells as a function of BRCA status after treatment with ABT-888/carboplatin. All RAD51 foci were analyzed by immunostaining after cells were treated with drugs for 24 h. (A) HCC1937 and HCC1937+BRCA1 treated with vehicle or 200 μM ABT-888/25 μM carboplatin. (B) EUFA423 and EUFA423+BRCA2 treated with vehicle or 12.5 μM ABT-888/12.5 μM carboplatin.

DOI: 10.1158/1535-7163.22498614

Authors: Caroline C. Clark, Jeffrey N. Weitzel, Timothy R. O'Connor

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362481247

Cites:

Cited by:

Related to: 10